MedTrace Logo

A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer

NCT06953765 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2025-05-01

No results posted yet for this study

Summary

In recent years, immunotherapy has made significant progress in the treatment of lung cancer, especially immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies) against non-small cell lung cancer (NSCLC). However, there are significant individual differences in patient response to treatment. Studies have shown that sleep disorders may affect the function of the immune system, thereby affecting tumor progression and treatment response. Therefore, the aim of this study was to evaluate the impact of sleep disturbances on lung cancer patients receiving immunotherapy.

Conditions

  • Lung Cancer (NSCLC)
  • Sleep Disorders, Circadian Rhythm
  • PD-1

Interventions

OTHER

PSQI

Prospective observational cohort study: Cohort o: Stratified according to baseline sleep disorder severity (PSQI score ≥7 vs. \<7).

OTHER

PQSI

PQSI-Sleep quality assessment scale

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Zilong Liu · Shanghai Zhongshan Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2028-12-30
Completion
2028-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06953765 on ClinicalTrials.gov